Tomoya Hatayama

Tomoya Hatayama

Auto-generated profile, based on publicly available information

Tomoya Hatayama

Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in IJU Case Reports
Verified
Journal Article
Open access
PDF file
THTomoya Hatayama
Tomoya Hatayama
THTetsutaro Hayashi
Tetsutaro Hayashi
SMShinji Matsuzaki
Shinji Matsuzaki
HMHiroshi Masumoto
Hiroshi Masumoto
HYHiroyuki Yanai
Hiroyuki Yanai
YHYasuhisa Hasegawa
Yasuhisa Hasegawa
Introduction: Small cell carcinoma of urinary bladder is rare and has an aggressive malignant behavior and poor prognosis. Advanced bladder cancers are treated with immune checkpoint inhibitors, however, its efficacy for small cell carcinoma of urinary bladder is unclear.Case presentation: A 54‐year‐old female, diagnosed with clinical stage T2N0M0 small cell carcinoma of urinary bladder, underwent radical cystectomy after three cycles of etoposide‐cisplatin neoadjuvant chemotherapy. Despite the fact that pathological examination revealed no residual carcinoma in bladder in her cystectomy specimen, local recurrence of a 60‐mm mass detected in the follow‐up investigation 7.5 months later. This was completely treated by pembrolizumab without any adverse effects. Immunohistochemical staining revealed that the tumor had no programmed death ligand 1 expression but it showed CD8‐positive T‐lymphocyte infiltration into the tumor.Conclusion: Immune checkpoint inhibitors might have curative potentials for treatment of small cell carcinoma of urinary bladder.

24 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
KMKoji Mita
Koji Mita
KIKouji Izumi
Kouji Izumi
AGAkihiro Goriki
Akihiro Goriki
RTRyo Tasaka
Ryo Tasaka
THTomoya Hatayama
Tomoya Hatayama
AMAtsushi Mizokami
Atsushi Mizokami
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear. To evaluate the agent that can be used as the first-line treatment for CRPC, an investigator-initiated, multicenter, randomized controlled trial (ENABLE Study for PCa) including both metastatic and nonmetastatic CRPC was conducted in Japan. The prostate-specific antigen (PSA) response rate, overall survival, some essential survival endpoints, and safety of patients with nonmetastatic CRPC were also analyzed. In this subanalysis, 15 and 26 patients in the ENZ and ABI arms, respectively, presented with nonmetastatic CRPC. There was no significant difference in terms of the PSA response rate between the ENZ and ABI arms (80% and 64%, respectively; p = 0.3048). The overall survival did not significantly differ between the two arms (HR: 0.68; 95% CI: 0.22–2.14, p = 0.5260). No significant differences were observed in terms of radiographic progression-free survival and cancer-specific survival between the ENZ and ABI arms (HR: 0.81; 95% CI: 0.35–1.84; p = 0.6056 and HR: 0.72; 95% CI: 0.19–2.73; p = 0.6443, respectively). Only four and six patients in the ENZ and ABI arms, respectively, had ≥grade 3 adverse events. ABI and ENZ had similar efficacy and safety profiles in patients with nonmetastatic CRPC.

17 July 2024 in International Journal of Urology
Verified
Journal Article
Open access
YKYuki Kohada
Yuki Kohada
HKHiroyuki Kitano
Hiroyuki Kitano
RTRyo Tasaka
Ryo Tasaka
SMShunsuke Miyamoto
Shunsuke Miyamoto
THTomoya Hatayama
Tomoya Hatayama
NHNobuyki Hinata
Nobuyki Hinata
Objectives: This study aimed to elucidate the clinical characteristics and predictors of long‐term postoperative urinary incontinence (PUI) after robot‐assisted radical prostatectomy (RARP).Methods: This study included patients who underwent RARP at our institution and were stratified into PUI (≥1 pad/day) and continence (0 pad/day) groups at 60 months after RARP. A propensity score‐matched analysis with multiple preoperative urinary status (Expanded Prostate Cancer Index Composite urinary subdomains, total International Prostate Symptom Score (IPSS), and IPSS‐quality of life scores) was performed to match preoperative urinary status in these groups. Serial changes in urinary status and treatment satisfaction preoperatively and until 60 months after RARP were compared, and predictors of long‐term PUI were assessed using multivariate logistic regression analysis.Results: A total of 228 patients were included in the PUI and continence groups (114 patients each). Although no significant difference in preoperative urinary status was observed between the two groups, the postoperative urinary status significantly worsened overall in the PUI group than in the continence group. Treatment satisfaction was also significantly lower in the PUI group than in the continence group from 12 to 60 months postoperatively. Multivariate logistic regression analysis revealed that age (≥70 years) and biochemical recurrence (BCR) were significant predictors of the long‐term PUI group (p < 0.05).Conclusions: Patients with long‐term PUI had poor overall postoperative urinary status and lower treatment satisfaction than the continence group. Considering the age and risk of BCR is important for predicting long‐term PUI when performing RARP.

20 February 2025 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
THTomoya Hatayama
Tomoya Hatayama
KGKeisuke Goto
Keisuke Goto
YKYuki Kohada
Yuki Kohada
KNKensuke Nishida
Kensuke Nishida
TUTakeshi Ueno
Takeshi Ueno
NHNobuyki Hinata
Nobuyki Hinata
Purpose: We aimed to evaluate the ability of the advanced lung cancer inflammation index (ALI) to predict the prognosis of patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). We also aimed to compare the ALI with other inflammatory or nutritional indices as prognostic indicators. Methods: We retrospectively evaluated patients who underwent RNU for UTUC at multiple centers between January 2010 and April 2024. We calculated the ALI before RNU and divided the patients into the low ALI and high ALI groups. We used 1:1 propensity score matching (PSM) to adjust the clinicopathological differences between two groups. We compared the overall survival (OS) and recurrence-free survival (RFS) of the low and high ALI groups using the Kaplan-Meier method. Furthermore, we assessed the ALI as a predictor of OS and RFS using a multivariate Cox proportional hazards regression analysis. Results: Of 488 patients (48.3% low ALI group), 160 patients from each group were matched. The Kaplan-Meier analysis revealed that the OS ( p = 0.009) and RFS ( p = 0.006) of the low ALI group were significantly shorter than those of the high ALI group. According to a multivariate analysis that included clinicopathological prognostic indicators, a low ALI was an independent predictor of poor OS ( p = 0.014) and RFS ( p = 0.038). Furthermore, according to the multivariate analysis including other inflammatory or nutritional indices, the ALI was an independent predictor of poor OS ( p = 0.024) and RFS ( p = 0.044). Conclusions: The ALI was a significantly useful prognostic predictors of patients with UTUC who underwent RNU.

1 January 2025 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Open access
MNMiki Naito
Miki Naito
HSHiroyuki Shikuma
Hiroyuki Shikuma
THTomoya Hatayama
Tomoya Hatayama
KYKazuma Yukihiro
Kazuma Yukihiro
KIKyosuke Iwane
Kyosuke Iwane
NHNobuyki Hinata
Nobuyki Hinata
Introduction: Laparoscopic adrenalectomy is a common procedure for the treatment of adrenal tumors. However, the recent inclusion of robotic adrenalectomy in the list of insurance‐covered procedures in Japan since April 2022 has raised questions regarding its broader clinical utility. This study aimed to elucidate the treatment outcomes of robotic adrenalectomy and conduct a comprehensive analysis comparing laparoscopic and robotic adrenalectomies. Methods: The baseline characteristics of patients and perioperative outcomes between laparoscopic and robotic adrenalectomies performed at Hiroshima University in July 2022 using the da Vinci Si, da Vinci Xi, and Hinotori were compared. Propensity score matching was performed to compare the outcomes of laparoscopic and robotic adrenalectomies. Results: Laparoscopic and robotic adrenalectomies were performed in 292 and 43 patients, respectively. There were no statistically significant differences between equipment. In the baseline characteristics of patients, the body mass index of the laparoscopic adrenalectomy group was smaller than that of the robotic adrenalectomy group. As for perioperative outcomes, the length of stay and number of complications were less for robotic adrenalectomy than for laparoscopic adrenalectomy. After matching for the body mass index, robotic adrenalectomy showed less bleeding and fewer intraoperative complications than laparoscopic adrenalectomy. However, after matching for general factors, patients with robotic adrenalectomy had shorter hospital stays and fewer intraoperative complications. Conclusions: Compared with laparoscopic adrenalectomy, robotic adrenalectomy can be performed safely with fewer intraoperative complications and may also have shorter hospital stays and minimal bleeding.

21 March 2024 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
THTomoya Hatayama
Tomoya Hatayama
KGKeisuke Goto
Keisuke Goto
KFKenta Fujiyama
Kenta Fujiyama
AGAkihiro Goriki
Akihiro Goriki
MKMayumi Kaneko
Mayumi Kaneko
KMKoji Mita
Koji Mita